Shareholders of Organon & Co. have cleared the merger deal with Sun Pharma, paving the way for the integration of the two companies.

Evercore ISI reports that talk of a potential deal between Sun Pharma and Organon & Co. (OGN) lacks confirmation and remains speculative.

Organon & Co. (OGN) is evaluating whether the launch of its product MIUDELLA can become a significant driver within the women's health markets.

Organon & Co. (OGN) stock has soared to a 52-week high following the announcement of an $11.75-billion merger with Sun.